Mercaptopurine
- Generic Name
- Mercaptopurine
- Brand Names
- Purixan, Xaluprine (previously Mercaptopurine Nova Laboratories)
- Drug Type
- Small Molecule
- Chemical Formula
- C5H4N4S
- CAS Number
- 50-44-2
- Unique Ingredient Identifier
- PKK6MUZ20G
- Background
An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
- Indication
For remission induction and maintenance therapy of acute lymphatic leukemia.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Promyelocytic Leukemia, Autoimmune Hepatitis, Crohn's Disease (CD), Lymphoblastic Lymphoma, Ulcerative Colitis
German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- Conditions
- Adult Acute Lymphocytic Leukemia
- Interventions
- Drug: Granulocyte-Colony-Stimulating FactorDrug: HDARACDrug: Depocyte
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- Goethe University
- Target Recruit Count
- 377
- Registration Number
- NCT00198978
- Locations
- 🇩🇪
University of Frankfurt, Medical Dept. II, Frankfurt, Germany
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93)
- Conditions
- Adult Acute Lymphocytic Leukemia
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2023-03-17
- Lead Sponsor
- Goethe University
- Target Recruit Count
- 720
- Registration Number
- NCT00199069
- Locations
- 🇩🇪
University Hospital, Medical Dept. II, Frankfurt, Germany
Study for Treatment of Cancer in Children With Ataxia-telangiectasia
- Conditions
- Ataxia-Telangiectasia
- Interventions
- Drug: dexamethasone, procarbazineProcedure: chemotherapy, intrathecal chemotherapy, steroid therapy
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2015-08-27
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 6
- Registration Number
- NCT00187057
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Total Therapy Study XIV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- Drug: Prednisone, Dexamethasone, Vincristine, Daunorubicin, PEG-L-asparaginase
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2011-03-30
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 53
- Registration Number
- NCT00187005
- Locations
- 🇺🇸
St.Jude Children's Research Hospital, Memphis, Tennessee, United States
A Study of Children With Refractory or Relapsed ALL
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- Drug: E. coli Asparaginase, PEG-L-asparaginaseProcedure: chemotherapy, intrathecal chemotherapy, steroid therapy
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2008-06-04
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT00187083
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Treatment for Patients With Stage III or IV Non-Hodgkin Lymphoma
- Conditions
- Lymphoblastic Lymphoma
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2008-04-23
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT00187122
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
CINJALL: Treatment for Children With Acute Lymphocytic Leukemia
- Conditions
- Acute Lymphocytic Leukemia
- Interventions
- Drug: Triple Intrathecal Therapy (MTX, Cytarabine, Hydrocortisone)
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Rutgers, The State University of New Jersey
- Target Recruit Count
- 60
- Registration Number
- NCT00176462
- Locations
- 🇺🇸
Jersey Shore University Medical Center, Neptune, New Jersey, United States
🇺🇸Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
A Study in Adults With Untreated Acute Lymphoblastic Leukemia
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 100
- Registration Number
- NCT00136435
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇨🇦Manitoba Blood & Marrow Transplant Program CancerCare Manitoba, Winnipeg, Manitoba, Canada
Applying Pediatric Regimens to Younger Adult Patients With Acute Lymphoblastic Leukemia (ALL)
- Conditions
- Lymphoblastic Leukemia, Acute
- Interventions
- First Posted Date
- 2005-08-17
- Last Posted Date
- 2008-11-14
- Lead Sponsor
- Japan Adult Leukemia Study Group
- Target Recruit Count
- 120
- Registration Number
- NCT00131053
- Locations
- 🇯🇵
Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Japan
High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL)
- Conditions
- Lymphoblastic Leukemia, Acute
- Interventions
- First Posted Date
- 2005-08-17
- Last Posted Date
- 2008-11-14
- Lead Sponsor
- Japan Adult Leukemia Study Group
- Target Recruit Count
- 240
- Registration Number
- NCT00131027
- Locations
- 🇯🇵
Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.